FRACTYL HEALTH, INC. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Fractyl Health reported positive clinical data for Revita: REMAIN-1 Midpoint Cohort randomized one-year data showed Revita-treated patients maintained 84% of GLP-1-induced weight loss versus 46% with sham (n=10 vs 8); REVEAL-1 open-label cohort maintained 78% (n=15). Pivotal Cohort topline six-month readout expected early Q4 2026, with potential FDA De Novo submission late Q4 2026. Cash position of $47.1M as of June 30, 2026 funds operations into early 2027. Q2 2026 net loss was $25.5M (vs $27.9M in Q2 2025); R&D expenses decreased $7.3M year-over-year to $13.8M.
Why this rating
Clinical data supports regulatory pathway for $50M-cap biotech; pivotal readout imminent. Positive but contingent on FDA De Novo approval risk.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.